Skip to main content

Table 6 Treatment-emergent adverse events

From: Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial

  Anidulafungin n = 43
  All-causality Treatment-related
Number of adverse events 150 12
Subjects with adverse events 35 9
Subjects with serious adverse events 16 1
Subjects with severe adverse events 13 0
Subjects discontinued due to adverse events 3 3
Subjects with dose reduced or temporary discontinuations due to adverse events 2 1
Deaths, n (%)  
  All causality 10 (23.3)